These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3124610)

  • 1. Interleukin 2 toxin: a step toward selective immunomodulation.
    Murphy JR; Kelley VE; Strom TB
    Am J Kidney Dis; 1988 Feb; 11(2):159-62. PubMed ID: 3124610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein.
    Bacha P; Williams DP; Waters C; Williams JM; Murphy JR; Strom TB
    J Exp Med; 1988 Feb; 167(2):612-22. PubMed ID: 3126255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 2-diphtheria toxin fusion protein can abolish cell-mediated immunity in vivo.
    Kelley VE; Bacha P; Pankewycz O; Nichols JC; Murphy JR; Strom TB
    Proc Natl Acad Sci U S A; 1988 Jun; 85(11):3980-4. PubMed ID: 3131768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell receptor specific targeted toxins: genetic construction and characterization of an interleukin 2 diphtheria toxin-related fusion protein.
    Murphy JR; Williams DP; Bacha P; Bishai W; Waters C; Strom TB
    J Recept Res; 1988; 8(1-4):467-80. PubMed ID: 3133472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein.
    Williams DP; Parker K; Bacha P; Bishai W; Borowski M; Genbauffe F; Strom TB; Murphy JR
    Protein Eng; 1987 Dec; 1(6):493-8. PubMed ID: 3334101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting diphtheria toxin to growth factor receptors.
    Murphy JR; vanderSpek JC
    Semin Cancer Biol; 1995 Oct; 6(5):259-67. PubMed ID: 8562903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diphtheria toxin receptor-binding domain substitution with interleukin 6: genetic construction and interleukin 6 receptor-specific action of a diphtheria toxin-related interleukin 6 fusion protein.
    Jean LF; Murphy JR
    Protein Eng; 1991 Dec; 4(8):989-94. PubMed ID: 1817263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic assembly and selective toxicity of diphtheria-toxin-related polypeptide hormone fusion proteins.
    Murphy JR; Bishai W; Williams D; Bacha P; Borowski M; Parker K; Boyd J; Waters C; Strom TB
    Biochem Soc Symp; 1987; 53():9-23. PubMed ID: 2847744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of human antigen-specific memory B cell response in vitro by a diphtheria toxin-related interleukin 2 fusion protein.
    Grailer AP; Nichols JC; Strom TB; Sollinger HW; Burlingham WJ
    Cell Immunol; 1991 Feb; 132(2):481-93. PubMed ID: 1988163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2-diphtheria toxin fusion protein prolongs murine islet cell engraftment.
    Pankewycz O; Mackie J; Hassarjian R; Murphy JR; Strom TB; Kelley VE
    Transplantation; 1989 Feb; 47(2):318-22. PubMed ID: 2493178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolongation of cardiac allograft survival in murine recipients treated with a diphtheria toxin-related interleukin-2 fusion protein.
    Kirkman RL; Bacha P; Barrett LV; Forte S; Murphy JR; Strom TB
    Transplantation; 1989 Feb; 47(2):327-30. PubMed ID: 2645719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 4 receptor targeted cytotoxicity: genetic construction and in vivo immunosuppressive activity of a diphtheria toxin-related murine interleukin 4 fusion protein.
    Lakkis F; Steele A; Pacheco-Silva A; Rubin-Kelley V; Strom TB; Murphy JR
    Eur J Immunol; 1991 Sep; 21(9):2253-8. PubMed ID: 1679715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Murine spontaneous T-cell leukemia constitutively expressing IL-2 receptor--a model for human T-cell malignancies expressing IL-2 receptor.
    Lugasi H; Hajos S; Murphy JR; Strom TB; Nichols J; Peñarroja C; Naor D
    Int J Cancer; 1990 Jan; 45(1):163-7. PubMed ID: 2298500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules.
    Strom TB; Kelley VR; Murphy JR; Nichols J; Woodworth TG
    Annu Rev Med; 1993; 44():343-53. PubMed ID: 8476255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.
    LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR
    Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia.
    LeMaistre CF; Rosenblum MG; Reuben JM; Parkinson DR; Meneghetti CM; Parker K; Shaw JP; Deisseroth AB; Woodworth T
    Lancet; 1991 May; 337(8750):1124-5. PubMed ID: 1674015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
    Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
    Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A kinetic analysis of the effects of interleukin-2 diphtheria toxin fusion protein upon activated T cells.
    Walz G; Zanker B; Murphy JR; Strom TB
    Transplantation; 1990 Jan; 49(1):198-201. PubMed ID: 2301012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward more selective therapies to block undesired immune responses.
    Strom TB; Kelley VE
    Kidney Int; 1989 Apr; 35(4):1026-33. PubMed ID: 2651766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.
    Kreitman RJ; Chaudhary VK; Waldmann TA; Hanchard B; Cranston B; FitzGerald DJ; Pastan I
    Leukemia; 1993 Apr; 7(4):553-62. PubMed ID: 8464234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.